financetom
Business
financetom
/
Business
/
What's Going On With Rocket Lab Stock After Earnings?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Rocket Lab Stock After Earnings?
Aug 9, 2024 8:29 AM

Rocket Lab USA, Inc. ( RKLB ) shares are trading higher Friday after the company reported better-than-expected financial results for the second quarter.

The Details:

Rocket Lab beat analyst expectations on the top and bottom lines with total revenue of $106.25 million, up 71% on a year-over-year basis. 

The company announced it has begun installation of the largest automated fiber placement machine of its kind into the company’s Neutron rocket production line in Middle River, MD. The AFP machine will enable Rocket Lab to automate production of the largest carbon composite rocket structures in history.

Rocket Lab also announced it has successfully hot fired its new rocket engine Archimedes for the first time, reaching a critical technical milestone toward the first launch of its new medium-lift rocket, Neutron. 

Read Next: What’s Going On With MicroStrategy Stock?

Rocket Lab shares are blasting higher on heavy volume Friday as investors digest the earnings report and business updates. According to data from Benzinga Pro, more than 7 million shares have already changed hands in the session, compared to the stock's 100-day average volume of 7.076 million shares.

RKLB Stock Prediction 2024:

Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.

Shares of Rocket Lab USA ( RKLB ) have an average 1-year price target of $5.94, representing an expected upside of 8.77%.

Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Rocket Lab USA ( RKLB ), while 6 analysts have bullish ratings. The street high price target from Roth MKM is $7, while the street low from Goldman Sachs is $4.50.

RKLB Price Action: According to Benzinga Pro, Rocket Lab shares are up 9.64% at $5.22 at the time of publication Friday.

Read Also:

The Trade Desk Stock Climbs After Better-Than-Expected Q2 Results

 Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Suburban Propane Partners' Fiscal Q4 Loss Narrows, Revenue Rises
Suburban Propane Partners' Fiscal Q4 Loss Narrows, Revenue Rises
Nov 13, 2025
07:51 AM EST, 11/13/2025 (MT Newswires) -- Suburban Propane Partners ( SPH ) reported a fiscal Q4 loss Thursday of $0.53 per diluted unit, narrower than the loss of $0.69 a year earlier. An analyst polled by FactSet expected a loss of $0.54. Revenue for the quarter ended Sept. 27 was $211.4 million, compared with $208.6 million a year earlier....
Vivani Medical reports wider Q3 net loss
Vivani Medical reports wider Q3 net loss
Nov 13, 2025
Overview * Vivani reports Q3 net loss widening to $6.5 mln, with increased operating expenses * Vivani secures $25.7 mln in cash and commitments for development projects Outlook * Vivani plans Phase 1 study of semaglutide implant in early 2026 * Company preparing for Phase 2 study pending Phase 1 results * Vivani expects Cortigent spin-off post-SEC operations resumption Result...
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
Nov 13, 2025
On Thursday, Scienture Holdings, Inc. ( SCNX ) reported financial results for the third quarter. Net revenue increased from approximately $65 thousand to $590 thousand, while gross profit increased from roughly $4 thousand to $575 thousand. Q3 was a transformational quarter for Scienture ( SCNX ) as we commenced sales of Arbli, commented Narasimhan Mani, President and Co-CEO of Scienture...
Arbutus Biopharma Narrows Q3 Net Loss, Revenue Drops
Arbutus Biopharma Narrows Q3 Net Loss, Revenue Drops
Nov 13, 2025
07:51 AM EST, 11/13/2025 (MT Newswires) -- Arbutus Biopharma ( ABUS ) on Thursday reported a Q3 net loss of $0.04 per diluted share, narrower than a loss of $0.10 a year earlier. Four analysts polled by FactSet expected a loss of $0.03. Revenue for the quarter ended Sept. 30 was $529,000, down from $1.3 million a year earlier. Three...
Copyright 2023-2026 - www.financetom.com All Rights Reserved